Related Experiment Video

Updated: Feb 5, 2026

Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis
08:26

Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis

Published on: January 21, 2020

7.2K

Drug-coated balloons versus stenting for intracranial atherosclerotic stenosis: a meta-analysis

Pablo Andrés Vega-Medina1, Jorge Eduardo Alonso Vera2,3, Laura Alexandra González-Chang1

  • 1School of Medicine, University of Panama, Panama City, Panama.

Journal of Neurointerventional Surgery
|February 3, 2026
PubMed

Insights

Drug-coated balloons (DCB/DEBs) show lower restenosis and recurrent stroke risk than stenting for intracranial atherosclerotic stenosis (ICAS). This endovascular approach may be safer, though long-term data are pending.

Area of Science:

  • Neurology
  • Interventional Cardiology
  • Vascular Surgery

Background:

  • Intracranial atherosclerotic stenosis (ICAS) is a major cause of ischemic stroke.
  • Stent angioplasty is a common treatment but carries risks like restenosis and thromboembolism.
  • Drug-coated balloons/drug-eluting balloons (DCB/DEBs) offer an alternative without permanent implants.

Purpose of the Study:

  • To compare clinical and procedural outcomes of DCB/DEBs versus stent angioplasty in patients with symptomatic ICAS.
  • To evaluate the efficacy and safety of DCB/DEBs as an endovascular treatment for ICAS.

Main Methods:

  • Systematic review and meta-analysis adhering to PRISMA guidelines.
  • Inclusion of six studies with 527 patients (233 DCB/DEB, 294 stenting).
  • Assessment of restenosis rates, periprocedural complications, and recurrent ischemic events.

Main Results:

  • DCB/DEBs significantly reduced restenosis risk (RR 0.25) compared to stenting.
  • No significant difference in periprocedural complications between DCB/DEBs and stenting (RR 0.65).
  • DCB/DEBs were associated with significantly fewer recurrent ischemic events (RR 0.30).

Conclusions:

  • DCB/DEBs demonstrate superior outcomes regarding restenosis and recurrent ischemic events for symptomatic ICAS.
  • This approach appears to be a potentially safer endovascular option than stenting, without increased periprocedural risks.
  • Further randomized trials are needed to establish long-term efficacy and definitive clinical practice guidelines.
Abstract

Keywords:
AngioplastyAtherosclerosisBalloonStent

More Related Videos

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents06:55

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents

Published on: October 26, 2016

9.5K
A Rabbit Aortic Valve Stenosis Model Induced by Direct Balloon Injury07:10

A Rabbit Aortic Valve Stenosis Model Induced by Direct Balloon Injury

Published on: March 31, 2023

1.6K

Related Concept Videos

Directing Effect of Substituents: meta-Directing Groups01:09

Directing Effect of Substituents: meta-Directing Groups

Substituents on the benzene ring that direct an incoming electrophile to undergo substitution at the meta position are called meta directors. All meta directors either have a positive charge on the atom directly bonded to the ring or a partial positive charge. These groups function by withdrawing electrons from the ring through inductive and resonance effects. Consider the carbocation intermediates formed upon the addition of an electrophile on nitrobenzene at the...
6.0K
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
655
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
207
Pinching-off of Coated Vesicles01:32

Pinching-off of Coated Vesicles

Vesicle budding is orchestrated by distinct cytosolic proteins such as adaptor proteins, coat proteins, and GTPases. To initiate vesicle budding, membrane-bending proteins containing crescent-shaped BAR domains bind to the lipid heads in the bilayer and distort the membrane to form a protein-coated vesicle bud. Adaptors proteins such as AP2 for clathrin-coated vesicles can nucleate on the deformed membrane. Finally, coat proteins such as clathrin or COPI and COPII assemble into a coat forming...
4.2K
Clathrin Coated Vesicles01:12

Clathrin Coated Vesicles

Clathrin-coated vesicles use endocytosis to transport receptors and lysosomal hydrolases from the Golgi to the lysosome in the late secretory pathway. Clathrin-mediated endocytosis was the first described endocytic process, and Clathrin-coated vesicles remain one of the most well-studied transport vesicles. The molecular machinery that generates clathrin-coated vesicles comprises over 50 proteins that precisely coordinate vesicle formation. Cell surface receptors concentrated in indented sites...
9.4K
COP Coated Vesicles00:59

COP Coated Vesicles

Membrane-enclosed structures called vesicles transport proteins and lipids across the cell. The vesicles derive their cargo from the plasma membrane, Golgi, ER, or endosome. Coated vesicles are spherical, protein-coated carriers with a 50–100 nm diameter that mediate bidirectional transport between the ER and the Golgi. The distribution of proteins between the ER and Golgi complex is dynamic and is maintained by different coated vesicles. Their formation is driven by the assembly of...
18.2K